Product Images Finasteride

This text provides information about the mean change from baseline in a study conducted to evaluate the efficacy and safety of a treatment. The data is presented in Figure 1, displaying symptom scores over a period of 4 years. The study includes a comparison between a placebo group and a group receiving finasteride. The specific values for each year are provided for both groups.*

Figure 3 shows the percentage of patients who developed acute urinary retention, both spontaneously and precipitated. The graph depicts the observation time in months on the x-axis and the percentage of patients on the y-axis. The data includes two groups: the Finasteride group and the Placebo group. The Finasteride group had a lower percentage of patients developing acute urinary retention compared to the Placebo group. The graph also displays the number of events cumulatively over time for each group, as well as the number of patients at risk each year.*

Figure 5 shows the cumulative incidence of a 4-point rise in AUA Symptom Score by treatment group. The graph displays the percent of participants experiencing this event over time, with the x-axis representing years from randomization and the y-axis indicating the percent with the event. The graph spans from 0 to 55 years.*